hydroxyurea has been researched along with Cancer of Head in 107 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected." | 3.75 | Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. ( Glick, JH; Taylor, SG; Zehngebot, LM, 1980) |
| "Eligible patients had newly diagnosed HNSCC." | 2.76 | A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers. ( Blair, EA; Cohen, EE; Haraf, DJ; Kunnavakkam, R; Salama, JK; Seiwert, T; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2011) |
| "Eligibility criteria were recurrence or a second primary tumor in a previously irradiated area, no major sequelae resulting from the first radiotherapy, good general condition, no distant metastasis, and salvage surgery with macroscopic complete resection." | 2.73 | Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. ( Bardet, E; Benhamou, E; Bensadoun, RJ; Bourhis, J; Castaing, M; de Raucourt, D; Dolivet, G; Ferron, C; Géry, B; Grégoire, V; Hamoir, M; Janot, F; Julieron, M, 2008) |
| "Hydroxyurea (HU) has been associated with fewer irreversible toxicities." | 2.73 | Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase in ( Beitler, JJ; Mazumdar, M; Owen, RP; Silver, CE; Smith, RV; Wadler, S, 2007) |
| "Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible." | 2.73 | Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008) |
| "Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy." | 2.72 | High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. ( Brockstein, B; Cohen, EE; Haraf, DJ; Kies, MS; Kocherginsky, M; List, MA; Mittal, BB; Rosen, F; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2006) |
| "Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible." | 2.71 | Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. ( Cooper, JS; Demas, W; Forastiere, AA; Garden, AS; Glisson, BS; Gore, E; Harris, J; Horwitz, EM; Jones, C; Nabell, L; Ridge, JA; Vokes, EE, 2004) |
| "The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery." | 2.70 | Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001) |
| "Patients with recurrent squamous cell cancer of the head and neck (SCH&N) are generally treated with systemic chemotherapy." | 2.70 | RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. ( Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2001) |
| "To achieve locoregional control of head and neck cancer, survival, and organ preservation using intensive concomitant chemoradiotherapy." | 2.69 | Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. ( Dolan, ME; Haraf, DJ; Hsieh, YC; Humerickhouse, R; Kies, MS; List, M; Mittal, BB; Pelzer, H; Stenson, K; Sulzen, L; Vokes, EE; Weichselbaum, RR; Witt, ME, 2000) |
| "The head and neck cancer program at the University of Chicago has reported encouraging results with concomitant 5-fluorouracil, hydroxyurea, and radiation administered every other week to patients with locally advanced or recurrent disease." | 2.68 | Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. ( Haraf, DJ; List, M; Stenson, K; Vokes, EE; Weichselbaum, RR; Witt, ME, 1997) |
| "The majority of patients with head and neck cancer die of locoregional recurrence of disease following surgery and/or radiotherapy." | 2.67 | Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; McEvilly, JM; Mick, R; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Hydroxyurea was substituted for bleomycin when the accumulative dose of bleomycin reached 400 units." | 2.65 | Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma. ( Gonzalez, MF; Sartiano, GP; Valdivieso, JG, 1984) |
| "The systemic therapy of head and neck cancer has gained momentum in recent years." | 2.42 | Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure. ( Argiris, A; Haraf, DJ; Kies, MS; Vokes, EE, 2003) |
| "At diagnosis of head and neck cancer, over half of all patients show advanced stages." | 2.40 | [Chemoradiotherapy for patients with advanced head and neck cancer]. ( Tsukuda, M, 1997) |
| "The common clinical presentations of head and neck cancer include early (stage I or II) disease, locally or regionally advanced (stage III or IV, M0) disease, and recurrent or metastatic disease (< 5% of patients)." | 2.40 | Oral 5-FU alternatives for the treatment of head and neck cancer. ( Brockstein, BE; Haraf, DJ; Humerickhouse, R; Vokes, EE, 1998) |
| "This paper presents an overview of studies of therapy of head and neck squamous cell carcinoma in which chemotherapy was combined with other modalities." | 2.35 | Current concepts of chemotherapy combined with other modalities for head and neck cancer. ( DeWys, WD, 1975) |
| "We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database." | 1.46 | Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. ( Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS, 2017) |
| "In this study, using HNSCC cell lines, we examined the anti-cancer effects and the mechanisms of action of docosahexaenoyl ethanolamide (DHEA) and N-arachidonoyl-L-alanine (NALA), which are polyunsaturated fatty acid (PUFA)-based ethanolamides like AEA." | 1.43 | 5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells. ( Hah, JH; Jeong, WJ; Oh, SM; Park, SW; Sung, MW, 2016) |
| "Skin cancer is the most common cancer, and often occurs in the head and neck region." | 1.35 | Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2. ( Fegn, L; Wang, Z, 2009) |
| "Locoregionally advanced, stage IV head and neck cancer has traditionally carried a poor prognosis." | 1.32 | Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. ( Brockstein, B; Fung, BB; Haraf, DJ; Kies, MS; Mittal, BB; Pelzer, H; Portugal, L; Rademaker, AW; Rosen, F; Stenson, KM; Vokes, EE; Weichselbaum, RW; Wenig, B; Witt, ME, 2004) |
| "Reirradiation of head and neck cancer with 5-fluorouracil and hydroxyurea offers acceptable acute toxicity and minimal late effects." | 1.30 | Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. ( Beenken, SW; Conner, W; Meredith, RF; Peters, GE; Salter, MM; Smith, J; Spencer, SA; Wheeler, RH, 1999) |
| "Head and neck cancer locally recurrent after previous irradiation and surgery presents a difficult management problem." | 1.28 | Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. ( Kim, RY; Meredith, RF; Peters, GE; Salter, MM; Spencer, SA; Weppelmann, B; Wheeler, RH, 1992) |
| "A cohort of 26 patients with head and neck cancer of all histologies were entered into a broad phase I study investigating simultaneous radiation therapy, 5-FU (with or without leucovorin), HU, and infusional cisplatin administered on an alternate-week schedule." | 1.28 | Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1992) |
| "Hydroxyurea is an active single agent in squamous cell cancer of the head and neck." | 1.28 | Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. ( Haraf, DJ; Panje, WR; Schilsky, RL; Vokes, EE; Weichselbaum, RR, 1992) |
| "Patients with cancer of nasopharynx had a better survival than those with other primaries (P = 0." | 1.28 | Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. ( Daniilidis, J; Destouni-Salem, E; Fountzilas, G; Kalogera-Fountzila, A; Sombolos, K; Sridhar, KS; Tourkantonis, A; Vritsios, A; Zaramboukas, T, 1990) |
| "Sixty-six patients with advanced head and neck cancer 57 of whom had failed to respond to prior irradiation, were treated according to two protocols." | 1.26 | [Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)]. ( Asselin, B; Bataini, JP; Brugère, J; Garcia-Giralt, E; Jaulerry, M; Jouve, M; Palangie, T; Pouillart, P, 1980) |
| "Thirty-two patients with squamous cell carcinoma of head and neck not amenable to surgery or radiotherapy were treated with a combination of methotrexate 0." | 1.26 | Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea. ( Alberto, P; Lehmann, W; Medenica, R, 1981) |
| "Ffty-three patients with head and neck cancer tested before radiation treatment to determine numbers of blood lymphocytes and immunologic responses to mitogens of lymphocytes in whole-blood cultures had mean values that were 19% to 26% less than values for healthy individuals." | 1.26 | Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy. ( Ellis, HN; Griffiths, CM; Jenkins, VK; Olson, MH; Perry, RR; Ray, P, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (39.25) | 18.7374 |
| 1990's | 30 (28.04) | 18.2507 |
| 2000's | 25 (23.36) | 29.6817 |
| 2010's | 9 (8.41) | 24.3611 |
| 2020's | 1 (0.93) | 2.80 |
| Authors | Studies |
|---|---|
| Rubin, A | 1 |
| Haroon, A | 1 |
| Rao, BK | 1 |
| Firoz, BF | 1 |
| Cohen, EE | 8 |
| Karrison, TG | 1 |
| Kocherginsky, M | 3 |
| Mueller, J | 1 |
| Egan, R | 1 |
| Huang, CH | 1 |
| Brockstein, BE | 7 |
| Agulnik, MB | 1 |
| Mittal, BB | 10 |
| Yunus, F | 1 |
| Samant, S | 1 |
| Raez, LE | 1 |
| Mehra, R | 1 |
| Kumar, P | 1 |
| Ondrey, F | 1 |
| Marchand, P | 1 |
| Braegas, B | 1 |
| Seiwert, TY | 5 |
| Villaflor, VM | 2 |
| Haraf, DJ | 32 |
| Vokes, EE | 40 |
| Sachdev, S | 1 |
| Refaat, T | 1 |
| Bacchus, ID | 1 |
| Sathiaseelan, V | 1 |
| Park, SW | 1 |
| Hah, JH | 1 |
| Oh, SM | 1 |
| Jeong, WJ | 1 |
| Sung, MW | 1 |
| Chen, JH | 1 |
| Yen, YC | 1 |
| Chen, TM | 1 |
| Yuan, KS | 1 |
| Lee, FP | 1 |
| Lin, KC | 1 |
| Lai, MT | 1 |
| Wu, CC | 1 |
| Chang, CL | 1 |
| Wu, SY | 1 |
| Salama, JK | 5 |
| Stenson, KM | 6 |
| Kistner, EO | 1 |
| Argiris, A | 3 |
| Witt, ME | 15 |
| Rosen, F | 4 |
| Janot, F | 3 |
| de Raucourt, D | 1 |
| Benhamou, E | 1 |
| Ferron, C | 1 |
| Dolivet, G | 1 |
| Bensadoun, RJ | 1 |
| Hamoir, M | 1 |
| Géry, B | 1 |
| Julieron, M | 2 |
| Castaing, M | 1 |
| Bardet, E | 1 |
| Grégoire, V | 1 |
| Bourhis, J | 2 |
| Fegn, L | 1 |
| Wang, Z | 1 |
| Kao, J | 3 |
| Genden, EM | 2 |
| Gupta, V | 2 |
| Policarpio, EL | 1 |
| Burri, RJ | 1 |
| Rivera, M | 2 |
| Gurudutt, V | 2 |
| Som, PM | 1 |
| Teng, M | 1 |
| Packer, SH | 2 |
| Blair, EA | 4 |
| Williams, R | 2 |
| Kunnavakkam, R | 1 |
| Seiwert, T | 1 |
| Choe, KS | 1 |
| Solanki, A | 1 |
| Portugal, L | 6 |
| Tong, CC | 1 |
| Lau, KH | 1 |
| Cannan, D | 1 |
| Aguirre-Ghiso, J | 1 |
| Sikora, AG | 1 |
| Forsythe, K | 1 |
| Ko, EC | 1 |
| Misiukiewicz, K | 1 |
| Teng, MS | 1 |
| Darga, T | 1 |
| Haraf, D | 2 |
| Stenson, K | 13 |
| Villaflor, V | 1 |
| Lingen, MW | 1 |
| Weichselbaum, RR | 24 |
| Spencer, S | 1 |
| Wheeler, R | 1 |
| Peters, G | 1 |
| Meredith, R | 3 |
| Beenken, S | 1 |
| Nabel, L | 1 |
| Wooten, A | 1 |
| Soong, SJ | 1 |
| Salter, M | 1 |
| Rosen, FR | 3 |
| Kies, MS | 8 |
| Rademaker, AW | 5 |
| List, MA | 4 |
| Fung, BB | 2 |
| Pelzer, H | 9 |
| Yang, WL | 1 |
| Yang-Biggs, G | 1 |
| Wu, Y | 1 |
| Ye, X | 1 |
| Gallos, G | 1 |
| Owen, RP | 2 |
| Ravikumar, TS | 1 |
| Garden, AS | 1 |
| Harris, J | 3 |
| Forastiere, AA | 1 |
| Ridge, JA | 1 |
| Jones, C | 1 |
| Horwitz, EM | 1 |
| Glisson, BS | 1 |
| Nabell, L | 1 |
| Cooper, JS | 1 |
| Demas, W | 1 |
| Gore, E | 1 |
| Brockstein, B | 5 |
| Wenig, B | 5 |
| Weichselbaum, RW | 2 |
| Faivre, S | 1 |
| Marti, A | 1 |
| Rixe, O | 1 |
| Gatineau, M | 1 |
| Temam, S | 1 |
| Armand, JP | 1 |
| Domenge, C | 2 |
| Luboinski, B | 2 |
| Raymond, E | 1 |
| Chmura, SJ | 1 |
| Milano, MT | 1 |
| Beitler, JJ | 3 |
| Smith, RV | 3 |
| Silver, CE | 2 |
| Mazumdar, M | 1 |
| Wadler, S | 3 |
| Spencer, SA | 4 |
| Wheeler, RH | 4 |
| Machtay, M | 2 |
| Schultz, C | 2 |
| Spanos, W | 2 |
| Rotman, M | 2 |
| Ang, KK | 1 |
| Mauer, A | 1 |
| Dekker, A | 2 |
| Chen, HX | 1 |
| Lipshutz, H | 3 |
| Lerner, HJ | 4 |
| Beckloff, GL | 2 |
| Pouillart, P | 1 |
| Palangie, T | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Bataini, JP | 1 |
| Jaulerry, M | 1 |
| Brugère, J | 1 |
| Asselin, B | 1 |
| Glick, JH | 1 |
| Zehngebot, LM | 1 |
| Taylor, SG | 1 |
| Veronesi, A | 1 |
| Barzan, L | 1 |
| Magri, MD | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Trovò, MG | 1 |
| Tumolo, S | 1 |
| Comoretto, R | 1 |
| Grigoletto, E | 1 |
| Medenica, R | 1 |
| Alberto, P | 1 |
| Lehmann, W | 2 |
| Eisenberger, MA | 1 |
| Denefrio, J | 1 |
| Silverman, M | 1 |
| Lessner, HE | 1 |
| Cruz, AB | 1 |
| Perkins, M | 1 |
| Aust, JB | 1 |
| Coltman, CA | 1 |
| Pollard, EB | 1 |
| Fletcher, WS | 1 |
| Kennedy, P | 1 |
| Lehane, DE | 1 |
| Mira, J | 1 |
| McCracken, JD | 1 |
| Sorgen, SD | 1 |
| Page, CP | 1 |
| Pendleton, OJ | 1 |
| Reddy, E | 1 |
| Sapp, J | 1 |
| Smith, F | 1 |
| Mead, GM | 1 |
| Jacobs, C | 1 |
| Vogl, SE | 1 |
| Camacho, F | 1 |
| Kaplan, BH | 1 |
| Lerner, H | 2 |
| Cinberg, J | 1 |
| Gonzalez, MF | 1 |
| Valdivieso, JG | 1 |
| Sartiano, GP | 1 |
| Stupp, R | 3 |
| Malone, D | 2 |
| Levin, J | 1 |
| Mick, R | 6 |
| McEvilly, JM | 2 |
| Aisner, J | 1 |
| Hiponia, D | 1 |
| Conley, B | 1 |
| Jacobs, M | 1 |
| Gray, W | 1 |
| Belani, CP | 1 |
| Moran, W | 1 |
| Sweeney, P | 1 |
| Kies, M | 2 |
| Moran, WJ | 3 |
| Kozloff, M | 2 |
| Mittal, B | 3 |
| Panje, W | 1 |
| Wong, WW | 1 |
| Haaz, MC | 1 |
| Fischel, JL | 1 |
| Formento, P | 1 |
| Renée, N | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| List, M | 3 |
| Tsukuda, M | 1 |
| Fasanmade, A | 1 |
| Glisson, B | 1 |
| Lippman, SM | 1 |
| Ratain, MJ | 3 |
| Sulzen, L | 4 |
| Klepsch, A | 1 |
| Athanasiadis, I | 1 |
| Humerickhouse, R | 2 |
| Haynes, H | 1 |
| Quish, A | 1 |
| Kotz, T | 2 |
| Serrano, M | 1 |
| Brook, A | 1 |
| Peters, GE | 2 |
| Beenken, SW | 1 |
| Meredith, RF | 2 |
| Smith, J | 1 |
| Conner, W | 1 |
| Salter, MM | 2 |
| Abraham, S | 1 |
| Dolan, ME | 1 |
| Hsieh, YC | 1 |
| Schaefer, U | 1 |
| Micke, O | 1 |
| Schueller, P | 1 |
| Willich, N | 1 |
| Eifel, PJ | 1 |
| Chung, T | 1 |
| Rademaker, A | 1 |
| Weichselbaum, R | 1 |
| De Crevoisier, R | 1 |
| Wibault, P | 1 |
| Koscielny, S | 1 |
| Lusinchi, A | 1 |
| Bobin, S | 1 |
| Eschwege, F | 1 |
| Price, LA | 1 |
| Hill, BT | 1 |
| Calvert, AH | 1 |
| Shaw, HJ | 1 |
| Hughes, KB | 1 |
| DeWys, WD | 1 |
| Goldsmith, MA | 1 |
| Carter, SK | 1 |
| Costanzi, JJ | 1 |
| Loukas, D | 1 |
| Gagliano, RG | 1 |
| Griffiths, C | 1 |
| Barranco, S | 1 |
| Johnson, CM | 1 |
| Harmon, JD | 1 |
| Pannuti, F | 1 |
| Cricca, A | 1 |
| Fruet, F | 1 |
| Burroni, P | 1 |
| Rossi, AP | 1 |
| Jenkins, VK | 1 |
| Ray, P | 1 |
| Ellis, HN | 1 |
| Griffiths, CM | 1 |
| Perry, RR | 1 |
| Olson, MH | 1 |
| Hussey, DH | 2 |
| Abrams, JP | 1 |
| Panje, WR | 6 |
| Buffoli, A | 1 |
| Morrica, B | 1 |
| Frata, P | 1 |
| La Face, B | 1 |
| Gebbia, V | 1 |
| Gebbia, N | 1 |
| Russo, A | 1 |
| Testa, A | 1 |
| Valenza, R | 1 |
| Zerillo, G | 1 |
| Ingria, F | 1 |
| Spadafora, G | 1 |
| Rausa, L | 1 |
| Beckett, M | 1 |
| Karrison, T | 1 |
| Weppelmann, B | 1 |
| Kim, RY | 1 |
| Schilsky, RL | 4 |
| Fountzilas, G | 3 |
| Daniilidis, J | 3 |
| Sridhar, KS | 1 |
| Kalogera-Fountzila, A | 2 |
| Zaramboukas, T | 1 |
| Sombolos, K | 1 |
| Destouni-Salem, E | 1 |
| Vritsios, A | 3 |
| Tourkantonis, A | 2 |
| Moormeier, JA | 1 |
| Egorin, MJ | 1 |
| Janisch, L | 1 |
| Hoffman, PC | 1 |
| Golomb, HM | 1 |
| Clavel, M | 1 |
| Ardiet, JM | 1 |
| Gignoux, B | 1 |
| Abele, R | 2 |
| Honegger, HP | 2 |
| Wolfensberger, M | 2 |
| Grossenbacher, R | 2 |
| Mermillod, B | 2 |
| Cavalli, F | 2 |
| Kaplan, E | 1 |
| Gervasi, A | 1 |
| Apostolidis, T | 1 |
| Nicolaou, A | 1 |
| Sridhar, K | 1 |
| Sideras, T | 1 |
| Haritanti, A | 1 |
| Anastasakis, C | 1 |
| Delis, V | 1 |
| Awan, AM | 2 |
| Goldman, MD | 1 |
| Tybor, AG | 1 |
| Guarnieri, CM | 1 |
| Dodion, P | 1 |
| Cognetti, F | 1 |
| van Rymenant, M | 1 |
| Dalesio, O | 1 |
| Kirkpatrick, A | 1 |
| Rozencweig, M | 1 |
| Boerrigter, GH | 1 |
| Heinerman, EC | 1 |
| Braakhuis, BJ | 1 |
| Snow, GB | 1 |
| Sullivan, RD | 1 |
| Bertino, JR | 1 |
| Mosher, MB | 1 |
| DeConti, RC | 1 |
| Simmonds, WP | 1 |
| Marchetta, FC | 1 |
| Stephens, FO | 1 |
| Goffinet, DR | 1 |
| Bagshaw, MA | 1 |
| Richards, GJ | 2 |
| Chambers, RG | 2 |
| Stefani, S | 1 |
| Eells, RW | 1 |
| Abbate, J | 1 |
| Scherer, E | 1 |
| Rassow, J | 1 |
| Samuels, ML | 1 |
| Godwin, MC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (REMATCH)[NCT05459415] | 54 participants (Anticipated) | Interventional | 2022-06-22 | Active, not recruiting | |||
| A Phase II Study of Efficacy and Safety of Induction Modified TPF (mTPF) Followed by Concurrent Chemoradiotherapy (CCRT) in Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)[NCT05527782] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-05-01 | Recruiting | ||
| A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT02460887] | Phase 3 | 236 participants (Anticipated) | Interventional | 2015-06-30 | Active, not recruiting | ||
| Neoadjuvant Tislelizumab With Afatinib for the Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Trial (neoCHANCE-1 Trial)[NCT05517330] | Phase 2 | 23 participants (Anticipated) | Interventional | 2022-12-20 | Recruiting | ||
| Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
| Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer[NCT00462735] | Phase 2 | 33 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| The Effect of Prophylactic Swallowing Exercises on Head and Neck Cancer Patients[NCT01349309] | 26 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia Induced by Targeted Therapy and Immunotherapy Combination Treatment[NCT04896528] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-06 | Recruiting | ||
| Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT03047265] | Phase 2 | 164 participants (Anticipated) | Interventional | 2017-02-04 | Active, not recruiting | ||
| A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol[NCT06087614] | Phase 2 | 124 participants (Anticipated) | Interventional | 2023-10-31 | Recruiting | ||
| Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck[NCT00002951] | Phase 2 | 53 participants (Actual) | Interventional | 1996-06-30 | Completed | ||
| Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658] | Phase 2 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants who did not have distant control (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) |
|---|---|
| Advanced Head and Neck Cancer | 21 |
Percentage of Participants with Loco-regional recurrence. (NCT00462735)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Advanced Head and Neck Cancer | 27 |
Grade 3 toxicities events (NCT00462735)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Advanced Head and Neck Cancer | 32 |
University of Washington Quality of Life (UW-QOLR) questionnaire - covers 12 domains - pain, appearance, activity, recreation, swallowing, chewing, speech, shoulder function, taste, saliva, mood and anxiety. Each domain have between 3 and 6 response options that are scaled evenly from 0 (worst) to 100 (best) according to the hierarchy of response and reported as one composite score from 0 (worst) to 100 (best). (NCT00462735)
Timeframe: 2 years
| Intervention | units on a scale (Mean) |
|---|---|
| Advanced Head and Neck Cancer | 80 |
Overall Survival - Percentage of Participants who survived Disease-Free Survival - measured from the initiation of nonsurgical treatment to either the last follow-up, disease progression, or death using intent-to-treat methodology (NCT00462735)
Timeframe: 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Overall Survival | Disease-Free Survival | |
| Advanced Head and Neck Cancer | 86 | 69 |
Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS
| Intervention | participants (Number) |
|---|---|
| Celecoxib 200mg | 0 |
| Celecoxib 400mg | 1 |
| Celecoxib 600mg | 2 |
Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Complete Response(CR) | Pathologic partial response (pPR) | Progressive disease (PD) | No evidence of disease (NED) | |
| Erlotinib + Celecoxib | 6 | 1 | 5 | 2 |
At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| locoregional control | progress-free survival | overall survival rates | long term toxicity | |
| Erlotinib + Celecoxib | 60 | 37 | 55 | 0 |
Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| free of disease | isolated locoregional progression | isolated distant progression | both locoregional and distant progression | no evidence of disease, died of comorbid illness | |
| Erlotinib + Celecoxib | 4 | 4 | 2 | 1 | 3 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
14 reviews available for hydroxyurea and Cancer of Head
| Article | Year |
|---|---|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2003 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Changing role of chemotherapy in treatment of head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Fl | 1982 |
The role of paclitaxel in the treatment of head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 1995 |
Fluorouracil modulation in head and neck cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Head and Neck Neoplasms; | 1993 |
Combined modalities in the treatment of head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials as Topic; Combined Modali | 1995 |
Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1995 |
[Chemoradiotherapy for patients with advanced head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Co | 1997 |
Oral 5-FU alternatives for the treatment of head and neck cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1998 |
Chemoradiation for carcinoma of the cervix: advances and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemotherapy, A | 2000 |
Current concepts of chemotherapy combined with other modalities for head and neck cancer.
Topics: Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Head; Head and Neck Neoplasms; | 1975 |
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck.
Topics: Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combination; Fluoro | 1975 |
Combination of chemotherapy with radiotherapy: review of previous studies and new perspectives.
Topics: Antineoplastic Agents; Bleomycin; Cisplatin; Combined Modality Therapy; Fluorouracil; Head and Neck | 1985 |
Clinical use of radiation sensitizing agents.
Topics: Animals; Antimetabolites, Antineoplastic; Bleomycin; Bromodeoxycytidine; Bromodeoxyuridine; Bromoura | 1974 |
40 trials available for hydroxyurea and Cancer of Head
| Article | Year |
|---|---|
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2014 |
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2008 |
Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Fem | 2008 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2011 |
Prognostic significance of p16 in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2012 |
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 2003 |
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2003 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2004 |
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2006 |
Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase in
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Dose Fractionation, R | 2007 |
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Fe | 2007 |
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2008 |
Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Chlorambucil; Clinical Trials as Topic; | 1980 |
Combination chemotherapy with bleomycin and hydroxyurea in the treatment of advanced head and neck cancer.
Topics: Ambulatory Care; Bleomycin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Therapy, Combin | 1982 |
Continuous intravenous infusion combination chemotherapy for head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin | 1984 |
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1994 |
Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1995 |
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1994 |
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 1996 |
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1997 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1998 |
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplat | 1998 |
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Dos | 1998 |
Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 1999 |
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1999 |
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease Progre | 2000 |
A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2000 |
Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo | 2001 |
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2001 |
RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality T | 2001 |
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisp | 1992 |
[Chemo-radiotherapy in advanced head and neck tumors. Personal experience].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cobalt Radioisotopes; Combin | 1992 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined M | 1992 |
A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1987 |
Induction chemotherapy with cisplatinum, 5-fluorouracil, bleomycin, mitomycin C and hydroxyurea for previously untreated locally advanced squamous cell carcinomas of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1989 |
Hydroxyurea and radiotherapy in head and neck cancer. Results of a prospective controlled study in 126 patients.
Topics: Adult; Clinical Trials as Topic; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle | 1971 |
54 other studies available for hydroxyurea and Cancer of Head
| Article | Year |
|---|---|
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R | 2022 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcino | 2015 |
5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-L-alanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells.
Topics: Alanine; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Arachidonic Acids; Azoles; B | 2016 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2017 |
Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and cyclo-oxygenase-2.
Topics: Administration, Topical; Analysis of Variance; Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxy | 2009 |
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch | 2011 |
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Development of cross-resistance between heat and cisplatin or hydroxyurea treatments in FaDu squamous carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Drug Resistance, Neoplasm | 2003 |
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; | 2003 |
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Com | 2004 |
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality | 2006 |
Hydroxyurea in the management of head and neck cancer. II. Surgical aspects.
Topics: Antineoplastic Agents; Head; Head and Neck Neoplasms; Humans; Hydroxyurea; Mandibular Neoplasms; Neo | 1967 |
[Chemotherapy of advanced head and neck cancer with a combination of bleomycin, vincristine, methotrexate and hydroxyuree or cis-dichloro-diamino-platinium. Analysis of local and general parameters of prognosis (author's transl)].
Topics: Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Head and Neck | 1980 |
Sequential combination chemotherapy of advanced head and neck carcinoma: re-evaluation of a highly effective regimen.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Doxorubicin; Female; Fluorouracil; Head and Neck N | 1981 |
Combined chemotherapy of head and neck squamous cell carcinomas with methotrexate, bleomycin, and hydroxyurea.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Drug Therapy, Combination; Head and Neck | 1981 |
Concurrent chemotherapy and radiation therapy of selected head and neck squamous cell carcinomas using bleomycin and hydroxyurea: A Southwest Oncology Group Study.
Topics: Adult; Aged; Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Therapy, Combin | 1982 |
Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug | 1983 |
Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.
Topics: Allopurinol; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Ce | 1996 |
Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1999 |
Pharyngeal transport dysfunction consequent to an organ-sparing protocol.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Deg | 1999 |
Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2000 |
Kinetically-based multiple drug treatment for advanced head and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Ear Neopla | 1975 |
Intravenous bleomycin infusion as a potential syncronizing agent in human disseminated malignancies: a preliminary report.
Topics: Adult; Bleomycin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Therapy, Combination; | 1976 |
Head and neck neoplasms: outpatient chemotherapy.
Topics: Ambulatory Care; Head and Neck Neoplasms; Humans; Hydroxyurea; Methotrexate | 1979 |
New polychemotherapy regimen for head and neck tumors: pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration | 1979 |
Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania hospital.
Topics: Carcinoma, Squamous Cell; Cell Division; Cell Line; DNA, Neoplasm; Head and Neck Neoplasms; Humans; | 1977 |
Lymphocyte response in patients with head and neck cancer: effect of clinical stage and radiotherapy.
Topics: Concanavalin A; Head and Neck Neoplasms; Humans; Hydroxyurea; Lectins; Leukocyte Count; Lymphocyte A | 1976 |
Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy.
Topics: Head and Neck Neoplasms; Humans; Hydroxyurea; Pilot Projects; Radiotherapy | 1975 |
Hydroxyurea modulates 5-fluorouracil antineoplastic activity in advanced head and neck carcinoma pretreated with chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 1992 |
The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.
Topics: Cell Survival; Combined Modality Therapy; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea | 1992 |
Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.
Topics: Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Head and | 1992 |
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Comb | 1992 |
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Topics: Administration, Oral; Bone Marrow; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Fluorouracil; H | 1992 |
Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1990 |
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Female; Flu | 1991 |
Induction chemotherapy with methotrexate, bleomycin and hydroxyurea with or without cisplatin in advanced squamous cell carcinoma of the head and neck: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1985 |
[Combined therapy of locally advanced squamous epithelial cancers in the area of the head and neck].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squam | 1988 |
Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcino | 1989 |
Concomitant hydroxyurea, 5-fluorouracil, and radiation therapy for recurrent head and neck cancer: early results.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1988 |
Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evaluati | 1986 |
Chemosensitivity of human head and neck cancer xenografts in the clonogenic assay and in nude mice.
Topics: Animals; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance | 1986 |
Chemotherapy in head and neck cancer.
Topics: Administration, Oral; Antineoplastic Agents; Arteries; Carcinoma, Squamous Cell; Head; Head and Neck | 1971 |
Chemotherapy of cancer of the head and neck.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Catheteriza | 1973 |
Chemotherapy in recurrent heat and neck cancer.
Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Drug Thera | 1974 |
Proceedings: Carcinoma of the oral cavity--general principles of therapy.
Topics: Azirines; Bleomycin; Carcinoma, Squamous Cell; Cryosurgery; Dactinomycin; Doxorubicin; Head and Neck | 1974 |
Combined chemotherapy, radiotherapy, and surgery in the treatment of advanced but localized solid malignant tumours.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cystadenocarcinoma; Drug Th | 1974 |
Hydroxyurea in the treatment of neoplasms of the head and neck. A resurvey.
Topics: Administration, Oral; Ear Neoplasms; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hydroxyurea | 1973 |
Six year survival in the combined treatment of far advanced head and neck cancer under a combined therapy program.
Topics: Carcinoma, Squamous Cell; Evaluation Studies as Topic; Head and Neck Neoplasms; Humans; Hydroxyurea; | 1973 |
[Basic principles of percutaneous radiotherapy in cervical lymph node metastases].
Topics: Carcinoma, Squamous Cell; Cesium Isotopes; Cobalt Isotopes; Electrons; Fluorouracil; Head and Neck N | 1971 |
Combined hydroxyurea and radiotherapy: a new dosage schedule.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Head; Head and Neck Neoplasms; | 1972 |
Three-year observation of combined treatment for far advanced cancer of the head and neck.
Topics: Carcinoma, Squamous Cell; Head; Head and Neck Neoplasms; Humans; Hydroxyurea; Mouth Neoplasms | 1969 |
Hydroxyurea: a radiosensitizer in the treatment of neoplasms of the head and neck.
Topics: Adult; Age Factors; Aged; Female; Gastrointestinal Diseases; Head; Head and Neck Neoplasms; Hematolo | 1969 |
Concomitant hydroxyurea and radiotherapy in the management of 60 patients with head and neck cancer.
Topics: Adult; Aged; Female; Gingival Diseases; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Maxillar | 1969 |